3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Multiple Myeloma
3
Carcinoma, Non-Small-Cell Lung
2
Smoldering Multiple Myeloma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Nasopharyngeal Carcinoma
1
Melanoma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Leukemia, Promyelocytic, Acute
1
Leukemia, Myeloid, Acute
1
Carcinoma, Squamous Cell
1
Interventions
Mitomycin
12
Gemcitabine
9
BCG Vaccine
4
apaziquone
3
Epirubicin
3
erdafitinib
2
durvalumab
2
dodecyl maltoside
2
VB4-845
2
Docetaxel
2
viscum album peptide
1
valrubicin
1
pirarubicin
1
hydroxycamptothecinum
1
Transurethral Resection of Bladder
1
Therapeutic Uses
1
Standard of Care
1
Saline Solution
1
Radiotherapy
1
Polysorbates
1
Maintenance
1
Magnetic Resonance Spectroscopy
1
Injections
1
Cystoscopy
1
5-aminolevulinic acid hexyl ester
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Non-Muscle Invasive Bladder Neoplasms
×
Maintenance
×
Clear all
NCT07207824
2025-10-06
HERO
Fudan University
Phase 3
Not yet recruiting
182 enrolled